---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070298"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T13:19:17.962306+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma reports $20.5M cash; strategic alternatives review ongoing

## Summary
- Cash and cash equivalents $20.5M as of March 31, 2025, with no outstanding debt.
- Strategic alternatives review continues since July 2024; Oppenheimer & Co. serving as exclusive financial advisor.
- Reduction-in-force progressing in stages as operational and strategic direction evolves.
- No assurance any transaction will result; updates only if completed or legally required.

## SEC filing metadata
- accession: 0000950170-25-070298
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017025070298/0000950170-25-070298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017025070298/meip-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070298
- JSON: https://secwatch.observer/filing/0000950170-25-070298.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.